Published in Blood on February 07, 2012
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | NCT00006400
Stroke With Transfusions Changing to Hydroxyurea | NCT00122980
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea (TWiTCH) | NCT01425307
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell | NCT02561312
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res (2013) 1.03
Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child (2014) 1.02
National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer (2012) 0.98
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood (2014) 0.96
Update on the use of hydroxyurea therapy in sickle cell disease. Blood (2014) 0.93
Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. Arch Dis Child (2013) 0.91
Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am (2013) 0.89
Current management of sickle cell anemia. Cold Spring Harb Perspect Med (2013) 0.87
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev (2013) 0.87
Novel insights in the management of sickle cell disease in childhood. World J Clin Pediatr (2016) 0.86
How I treat and manage strokes in sickle cell disease. Blood (2015) 0.83
Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis (2013) 0.82
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev (2015) 0.80
Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk. Am J Hematol (2013) 0.80
Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol (2015) 0.80
A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther (2015) 0.80
Whole exome sequencing identifies novel genes for fetal hemoglobin response to hydroxyurea in children with sickle cell anemia. PLoS One (2014) 0.80
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Res Protoc (2016) 0.77
Sickle cell disease: looking back but towards the future. Rev Bras Hematol Hemoter (2012) 0.77
Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke. PLoS One (2015) 0.77
Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol (2015) 0.77
Biologic complexity in sickle cell disease: implications for developing targeted therapeutics. ScientificWorldJournal (2013) 0.77
Hydroxycarbamide: clinical aspects. C R Biol (2012) 0.76
Treatment for sickle cell disease in Africa: should we invest in haematopoietic stem cell transplantation? Pan Afr Med J (2014) 0.76
Adolescents with sickle cell anaemia: Experience in a private tertiary hospital serving a tertiary institution. Niger Med J (2015) 0.75
Genetic stroke syndromes. Continuum (Minneap Minn) (2014) 0.75
To SWiTCH or not to SWiTCH? Blood (2012) 0.75
Arterial ischemic stroke in children: risk factors and etiologies. Curr Neurol Neurosci Rep (2014) 0.75
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS One (2016) 0.75
Pediatric sickle cell disease: past successes and future challenges. Pediatr Res (2016) 0.75
Cellular therapy for sickle cell disease. Cytotherapy (2016) 0.75
Contribution of Sickle Cell Disease to the Pediatric Stroke Burden Among Hospital Discharges of African-Americans-United States, 1997-2012. Pediatr Blood Cancer (2015) 0.75
Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease. Mediterr J Hematol Infect Dis (2017) 0.75
Examination of Reticulocytosis among Chronically Transfused Children with Sickle Cell Anemia. PLoS One (2016) 0.75
Neurologic complications of sickle cell disease in Africa: A systematic review and meta-analysis. Neurology (2017) 0.75
Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Res Protoc (2017) 0.75
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease. PLoS One (2017) 0.75
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood (1998) 6.72
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood (2004) 4.40
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med (2005) 3.38
How I use hydroxyurea to treat young patients with sickle cell anemia. Blood (2010) 2.68
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr (2004) 2.65
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics (2008) 2.42
Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood (1990) 2.38
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med (2008) 2.31
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood (2010) 2.15
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr (1992) 2.02
The natural history of stroke in sickle cell disease. Am J Med (1978) 1.97
Longitudinal analysis of heart and liver iron in thalassemia major. Blood (2008) 1.94
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer (2011) 1.89
Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood (2000) 1.84
Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood (2010) 1.69
Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood (1999) 1.57
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr (2002) 1.50
Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am (2008) 1.43
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr (1995) 1.43
Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol (2001) 1.42
Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol (1991) 1.32
Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: frequency, characteristics and significance. Br J Haematol (1999) 1.28
Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. J Pediatr (2010) 1.21
Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med (2010) 1.11
High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr (1991) 1.03
Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr (1980) 0.98
Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol (2011) 0.98
Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood (2000) 0.87
Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol (1995) 0.83
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer (2011) 1.89
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Genetic predictors for stroke in children with sickle cell anemia. Blood (2011) 1.12
Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr (2002) 1.07
A method for fitting regression splines with varying polynomial order in the linear mixed model. Stat Med (2006) 1.05
Estimating correlation by using a general linear mixed model: evaluation of the relationship between the concentration of HIV-1 RNA in blood and semen. Stat Med (2003) 0.97
Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood (2014) 0.96
Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol (2008) 0.88
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol (2012) 0.80
Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia. J Pediatr (2011) 0.80
Hydroxycarbamide: clinical aspects. C R Biol (2012) 0.76
Making inferences about projected completors in longitudinal studies. J Biopharm Stat (2004) 0.75